Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 10, 2014; 5(3): 440-454
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.440
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.440
Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions
Gonzalo Recondo Jr, Enrique Dìaz Canton, Màximo de la Vega, Martin Greco, Gonzalo Recondo Sr, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), 4102 Buenos Aires, Argentina
Enrique Dìaz Canton, Màximo de la Vega, Fundaleu, Fundación para Combatir la Leucemia, Servicio de Oncología Clínica, 4102 Buenos Aires, Argentina
Matias E Valsecchi, Medical Oncology, HIMG, Huntington, WV 25705, United States
Author contributions: Recondo G Jr, Dìaz Canton E, de la Vega M and Valsecchi ME conceived the topic, contributed to the writing and revising, and provided overall design and execution of the manuscript; Greco M and Recondo G Sr contributed to the writing and revising of the manuscript.
Correspondence to: Matias E Valsecchi, MD, MS, Medical Oncology, HIMG, 5170 US Route 60 East, Huntington, WV 25705, United States. meval78@yahoo.com
Telephone: +1-304-3994647 Fax: +1-304-3992390
Received: December 27, 2013
Revised: March 4, 2014
Accepted: April 17, 2014
Published online: August 10, 2014
Processing time: 217 Days and 2.7 Hours
Revised: March 4, 2014
Accepted: April 17, 2014
Published online: August 10, 2014
Processing time: 217 Days and 2.7 Hours
Core Tip
Core tip: This is a review manuscript with the most updated information regarding the state of the art management of human epidermal growth factor receptor-2 positive breast cancer. It summarizes the most relevant and updated information derived from more than 40 phase II and III clinical trials that constitute the theoretical framework to support our daily practice. It also highlights some key clinical concepts that should not be overlooked by critically appraising the current literature. Finally, it gives the reader with a compilation of potential new agents that are currently being tested and may soon become the next step in the battle against this disease.